Background and Purpose-Our objective was to study nationwide utilization trends of computed tomographic (CT) angiogram (CTA) and CT perfusion (CTP) in acute ischemic stroke and particularly in the context of use of reperfusion therapies. Methods-We reviewed the Premier Perspective Database for ischemic stroke-related hospitalizations of adult patients during a 5-year period, 2006 to 2010. Use of multimodal CT-based imaging and reperfusion therapies was determined through the procedure and billing codes. Logistic regression was used to identify predictors of utilization of imaging studies and reperfusion treatments. Results-An increasing proportion of ischemic strokes received CTA each year: 3.8% in 2006, 5.6% in 2007, 6.5% in 2008, 7.5% in 2009, and 9.1% in 2010 (P<0.0001 
A cute ischemic stroke is the leading cause of serious long-term disability, and on average, 1 American dies from stroke every 4 minutes. 1 Intravenous thrombolysis treatment with recombinant tissue-type plasminogen activator (r-tPA) is the only Food and Drug Administration-approved treatment and is used in only 5% of patients with acute stroke attributable to a narrow 4.5-hour treatment window. 2, 3 Multimodal computed tomography (CT) and MRI including perfusion studies have offered the promise of increasing eligibility for acute reperfusion therapies for ischemic stroke, including the possibility of extending the time window for intravenous r-tPA and better selecting patients for endovascular therapies.
To date, the majority of randomized controlled trials using multimodal imaging for thrombolytic treatment selection have used magnetic resonance (MR)-based imaging. [4] [5] [6] Although favorable trends were seen in some of the MR selection-based trials, no clinical benefit was demonstrated. 6 A prospective cohort study using MR selection demonstrated favorable clinical outcomes. 7 However, most recently, the randomized controlled phase II MR Rescue trial tested imaging selection for endovascular therapy using both MR and CT perfusion (CTP) and showed no evidence for the imaging selection hypothesis. 8 No clinical trials have tested CT-based multimodal imaging exclusively, and thus the usefulness of CT-based imaging in making acute stroke treatment decisions is especially lacking.
Although randomized studies regarding its usefulness have been limited, CT-based multimodal imaging, including CT angiogram (CTA) and CTP, can be easily assimilated into routine clinical practice of stroke evaluation and treatment. As compared with MRI, CT scanners are typically more widely available, more easily accessible to most emergency departments, faster to complete, less medically contraindicated, and have lower costs. Utilization data on CT-based neuroimaging for acute stroke in the United States have been limited.
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We hypothesized that both CTA and CTP use in acute stroke setting may be increasing in the United States during the last few years, despite the lack of evidence supporting their use in acute treatment decisions. In support of its use for treatment decisions, we hypothesized that imaging rates particularly for CTP would be higher among cases treated with acute stroke reperfusion compared with those not treated with reperfusion therapies. We sought to determine nationwide utilization trends of CTA and CTP imaging in acute ischemic stroke and particularly in the context of reperfusion therapies.
Methods
Data
We reviewed a national hospital administrative database (Premier Perspective Database, Charlotte, NC). The Premier Hospital data set is the largest clinical and operational data warehouse in the nation developed for measuring quality and use of health care and contains longitudinal inpatient and ambulatory data pertaining to all discharges from >600 hospitals representing ≈20% of all discharges nationwide (https://www.premierinc.com/wps/portal/premierinc/public/ transforminghealthcare/improvingperformance/servicesprograms/ researchservices). Participating hospitals represent all regions of the United States and are predominantly small-to-midsize nonteaching facilities that serve largely urban patient populations. This nationally representative database are as follows: rural (25%) versus urban (75%); nonteaching (72.6%) versus teaching (27.4%); and number of beds, 0 to 99 (18.2%), 100 to 299 (43.3%), 300 to 499 (26.2%), 500+ (12.3%). The hospital characteristics are representative of those within the annual survey of hospitals in the United States by the American Hospital Association. 9 Unlike individual insurance databases, Premier Perspective data are not limited by payer status. Each patient record in Premier includes a complete list of International Classification of Diseases, Ninth Revision (ICD-9) diagnosis and procedure codes, comprehensive line item billing data, payer information, and patient demographics. This work is Institutional Review Board exempt because it used previously exempted, deidentified data without any protected health information.
Study Population
We extracted and reviewed data from the Premier Database for a 5-year period of 2006 to 2010 fiscal years. The inclusion criteria included ischemic stroke with primary ICD-9 codes and first hospitalization and discharge date between 2006 and 2010. The exclusion criteria included patients aged <18 years and patients who received only MRI/MR angiography as part of the workup. Ischemic strokerelated hospitalizations were defined by ICD-9 codes 433.x1, 434. x1, and 436 in the primary position. These ICD-9 codes have a high positive predictive value (>85%) and are recommended by the US Food and Drug Administration Mini-Sentinel project to identify acute ischemic stroke in administrative data sets.
10
Imaging Variables
For the purpose of this study, we determined the number and type of neuroimaging studies performed by analyzing billing claims. Use of CT-based imaging on day 1 (admission day) or day 2 of hospitalization was determined based on billing codes for the CT head, CTA head, CTA head and neck, and CTP imaging.
Patient Demographics and Hospital Characteristics
We compared the following patient demographics of those who underwent CTP versus CTA versus CT head alone: age, sex, race, type of health insurance, and hospital characteristic to include teaching status, number of beds, and location (urban/rural).
Treatments
Reperfusion treatments were divided into 2 categories: (1) thrombolysis (intravenous and intra-arterial) and (2) mechanical clot disruption and extraction using embolectomy devices (with or without thrombolysis). We determined the use of reperfusion therapies by reviewing thrombolysis diagnosis and procedure codes (ICD-9, 99.10; current procedural terminology, 37195), pharmacy records (use of 50 or 100 mg alteplase vials), hospital billing information (notation of the Penumbra or MERCI device because these were the only mechanical embolectomy devices available in 2010 or earlier), and the mechanical thrombectomy procedure code (ICD-9, 39.74).
Statistical Analysis
Descriptive analyses involving frequencies and percentages were used to describe trends in utilization of imaging studies and reperfusion treatments for fiscal years 2006 to 2010. Temporal trends of binomial proportions were assessed using the Cochran-Armitage trend test. Associations between categorical variables were assessed using the χ 2 test, and mean values of continuous variables were compared across groups using the ANOVA test. Logistic regression was used to identify predictors of utilization of imaging studies and reperfusion treatments. SAS version 9.3 (SAS Institute Inc, Cary, NC) was used for all calculations, and the significance level was set at 0.05. Figure 1 and Table 1 ).
Baseline Characteristics of Population
Patients with ischemic stroke who received CTA and CTP, as compared with CT head alone, were younger, more frequently males, of white race, were less likely to be on Medicare insurance, were similarly distributed between urban and rural hospitals, and were more frequent at teaching hospitals ( Table 2,  Table I in the online-only Data Supplement).
Reperfusion Trends in Study Population
Reperfusion treatment was more common among those who were imaged with CTA (13.0%) and CTP (17.6%) compared with those with CT head alone (4.0%; P<0.0001). Specifically, higher rates of r-tPA were observed in those imaged with CTA (10.2%) and CTP (11.4%) compared with those with CT head alone (3.8%; P<0.0001). Similarly, higher rates of mechanical embolectomy were observed in those imaged with CTA (2.8%) and CTP (6.3%) compared with those with CT head alone (0.2%; P<0.0001; Table 3 and Figure 2 ). The total number of patients who received overall reperfusion among CTA group was higher in teaching versus nonteaching hospitals: Logistic regression analysis demonstrated that the odds of utilization of CTA and CTP increased temporally during the study period and was higher in males, whites, younger patients, and those with non-Medicare insurance. Utilization was also 
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higher at teaching hospitals. Similarly, odds of reperfusion treatment with r-tPA and mechanical embolectomy were higher in males, whites, younger patients, those with non-Medicare insurance, and those at teaching hospitals (Table 4) .
Discussion
We found a marked increase in CTA/CTP use; there was a 142% increase in CTA and a 6429% increase in CTP use in the United States during a 5-year period (2006-2010) as compared with only a 1.40% increase in the total number of hospitalized ischemic strokes. These results suggest that CTA and CTP imaging are being rapidly assimilated into clinical practice and that patients with CTA/CTP have a higher association with reperfusion treatments. The increased rates of CTA/CTP in this study are consistent with prior studies showing a marked nationwide overall increase in use of CT and MR imaging in the past decade. 11, 12 However, to the best of our knowledge, this is the first study showing utilization trends of CTA and CTP for evaluation of acute ischemic stroke. Tripling of CTP from 2007 to 2010 as seen in our study also mirrors the technological advances in CT scanners in the past few years. The newer scanners are faster, and they provide increased brain coverage suitable for perfusion imaging along with more sophisticated postprocessing tools.
The one stop shop of CT head, CTA, and CTP providing information about intracranial hemorrhage, vascular occlusion, and tissue at risk, along with speed and the ubiquitous availability of CT scanners, gives CT a distinct advantage over MRI in evaluation of acute stroke. However, CT-based multimodal imaging has some greater risks including radiation and a small risk of nephrotoxicity, and study of its clinical implications has been limited compared with MRI. 13, 14 The majority of the current evidence supporting the use of CTP comes from case series and case registries and not from definitive trials. [15] [16] [17] A recent phase 2 randomized trial of tenecteplase versus alteplase for acute stroke used CTP as a eligibility criteria; however, the trial did not include a study arm of patients without CTP imaging. 18 One of the challenges of using CTP is wide variability in the quantitative methods used for CTP analysis and poor reliability in measuring irreversible cerebral infarction. 19, 20 Given this lack of standardization and validation of perfusion imaging and the fact that using imaging to guide acute stroke treatment remains unproven, the increased rates of imaging observed raise important questions about current practice.
Increased use of imaging and its associated costs is a growing concern among the payers and policy makers. 21 The cost of inpatient stroke care climbed by 42% between 1997 and 2007, and neuroimaging was the fastest growing component of the hospitalization cost. 12 Recent imaging guidelines in acute stroke suggest CTA may be considered, provided it does not delay time to treatment (class I, level A evidence), but caution against routine use of CTP for clinical decision The variables of urban location vs rural and number of beds of the admitting hospital were not included because they correlate highly with teaching status of the hospital. CI indicates confidence interval; CTA, computed tomographic angiogram; CTP, CT perfusion; OR, odds ratio; and r-tPA, recombinant tissue-type plasminogen activator. making (class IIb, level B evidence). 22, 23 It could be argued that the increase in rates of CTA studies in our study could potentially be unrelated to decisions about endovascular interventions because CTA can also help in diagnostic evaluation or to guide long-term management. CTP would typically be done on patients with acute stroke who are potential candidates for endovascular therapies. However, we found that reperfusion treatments including r-tPA and mechanical embolectomy were more common in both CTA and CTP groups as compared with those with CT head alone. The finding that CTA and CTP were more frequently used at larger teaching hospitals is not surprising given that large academic centers are better equipped with neurointerventional stroke treatment options. Because the database used in this study has a heavy representation of small-to-midsize community nonacademic hospitals, the numbers may actually under-represent the percentage of CTA and CTP performed in the United States.
Our study has several important limitations. Because we used an administrative data set without specific clinical information on the patients, CTA/CTP studies were neither linked to physician rationale for ordering the imaging study nor linked to patient outcomes; the clinical indications for reperfusion therapies were also unavailable. Therefore, it is not clear whether high utilization of CTA/CTP translates to improved health outcomes, although controlled studies suggest no clinical benefit. Also, we could not correlate the use of CTP with CTA variables including vascular status. Transfer between hospitals was difficult to evaluate, and only the final receiving acute care hospital's use of imaging was included in this analysis. Another limitation is that we did not compare the utilization rates of CT and MR perfusion studies. The lack of a current procedural terminology or billing code for MR perfusion studies made it difficult to make an accurate comparison. We did not address the costs and cost-effectiveness analysis of CTA/CTP; however, this was not the focus of our study. Additional limitations include the use of small, retrospective database, and future prospective studies using a larger data set are needed to confirm our findings. Although the concordance between administrative coding data and medical records for stroke has been validated, we recognize that administrative coding data relies on the accuracy of the diagnosis, quality of included data elements, and missing data elements. [24] [25] [26] Despite these intrinsic limitations, nationwide administrative databases are a practical and cost effective tool for studying national practice patterns.
Our documentation of utilization rates and associated factors provide the critical benchmarks to understand current practice patterns, do cost studies, and plan future clinical trials related to multimodal imaging. Given the discrepancy of increasing use and lack of evidence-based guidelines, CT-based multimodal imaging needs to be investigated further in large randomized controlled trials to determine its efficacy to guide treatment decisions and improve patient outcomes; this is an urgent need and a fertile ground for further research.
Conclusions
CTA use tripled and CTP use increased >50-fold from 2006 to 2010, and both were associated with increased reperfusion therapy use. Given limited healthcare resources, the wellpublicized risks of increased radiation, along with limited evidence for clinical benefit of this approach, it becomes imperative that CT-based multimodal imaging selection for acute ischemic strokes be studied in controlled clinical trials.
